DOA
IMUC

D'Orazio & Associates’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

D'Orazio & Associates’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-75
Closed – – 354
2017
Q2 		$0 Hold
75
– – ﹤0.01% 359
2017
Q1 		$0 Hold
75
– – ﹤0.01% 311
2016
Q4 		$0 Hold
75
– – ﹤0.01% 303
2016
Q3 		$0 Hold
75
– – ﹤0.01% 320
2016
Q2 		$1K Hold
75
– – ﹤0.01% 290
2016
Q1 		$0 Buy
+75
New +$844 ﹤0.01% 333

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

D'Orazio & Associates's IMUC Position: Q3 2017 in Review

D'Orazio & Associates sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2017, closing a stake of 75 shares.

D'Orazio & Associates first reported a position in IMUC in Q1 2016 and held it in 6 quarters. The position peaked at $1K in Q2 2016. 18 funds tracked by Wall St. Rank hold IMUC as of Q3 2017.

  • D'Orazio & Associates reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2017 after selling out during the quarter.
  • D'Orazio & Associates sold 75 ImmunoCellular Therapeutics, Ltd. shares in Q3 2017.
  • D'Orazio & Associates first reported a position in ImmunoCellular Therapeutics, Ltd. in Q1 2016 and held it in 6 quarters.
  • D'Orazio & Associates's ImmunoCellular Therapeutics, Ltd. position peaked at $1K in Q2 2016.
  • 18 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2017.

Based on D'Orazio & Associates's 13F filing for Q3 2017, filed 14 Nov 2017.